Articles tagged with Breast Cancer
The Hamilton researchers used state-of-the-art computational techniques to design molecules that were predicted to be effective against breast cancer. These molecules, later synthesized by Albany Medical College scientists, showed promise as anti-breast cancer compounds in animal systems.
A recent US study reveals a downturn in breast cancer incidence rates above 45 years old starting in 1998/1999, consistent with reduced mammography utilization. The study suggests that the decline is partly due to the early benefit of decreased hormone replacement therapy (HRT) use.
Researchers at Baylor College of Medicine have developed a new treatment approach that combines three drugs to block the HER-2 receptor, eradicating aggressive breast tumors in mice. The treatment, known as targeted therapy, has shown promising results, with tumors disappearing and not returning even after treatment is stopped.
Researchers have confirmed that tamoxifen prevents breast cancer in high-risk women, while a combination of three HER inhibitors slows down tumor growth. Additionally, chemotherapy with rituximab improves overall survival rates for patients with indolent lymphoma, and new lung cancer risk prediction models offer modest accuracy.
A new protein fragment called pHLIP has been demonstrated to target and accumulate in human breast tumors, enabling detection and potentially treating cancer. The protein's ability to navigate acidic environments makes it a promising tool for detecting various disease states.
A study by Washington State University found that Iyengar yoga reduces demands of illness and stimulates lower lymphocyte NF-?B activation in breast cancer survivors, indicating improved immune function and quality of life. The practice has also been shown to decrease physical and emotional burdens associated with cancer survivorship.
A large study of 28,000 Danish utility workers found no evidence of increased cancer risk from low-frequency electromagnetic fields. However, women exposed to medium frequency fields were more likely to develop brain cancer than those with lower exposure levels.
A new animal study reveals that moderate alcohol consumption significantly increases breast cancer tumor size and angiogenesis, providing insights into the mechanisms of alcohol-induced breast cancer. The study confirms that even low levels of EtOH intake can stimulate tumor growth and malignancy.
Researchers found that leptin upregulates E-cadherin in breast tissue, promoting tumor growth and cell aggregation. This link between obesity, leptin, and breast cancer suggests new targets for drug intervention.
Scientists have found a new hereditary breast cancer gene, TWIST1, linked to Saethre-Chotzen syndrome, increasing breast cancer risk by nearly twenty times. Early mammograms are now recommended for young women with the syndrome to detect breast cancer at an early stage.
A study of 105,716 premenopausal women found no association between abortion or miscarriage and breast cancer risk. Women who carried a pregnancy to term may have a reduced lifetime risk of breast cancer due to accelerated breast cell differentiation.
Researchers at MGH Cancer Center have discovered a molecular pathway underlying sensitivity to cisplatin in triple-negative breast cancers. The study found that p63 and p73 expression levels can predict cisplatin therapy effectiveness, leading to the design of a clinical trial for patients with advanced triple-negative breast cancer.
Triple-negative breast cancer cells are sensitive to cisplatin, a common chemotherapeutic drug that can be effective in treating the disease. Researchers also found that delta-Np63 and TAp73 proteins play a crucial role in mediating chemosensitivity to cisplatin.
Researchers have identified two genes associated with a poor response to radiotherapy in breast cancer treatment. The test could help warn patients of an increased risk and offer alternative treatments.
Triple-negative breast cancer cells are sensitive to cisplatin due to increased expression of delta-Np63 and TAp73 proteins. Cisplatin releases TAp73 from delta-Np63, leading to cell death. This study suggests using cisplatin as an early treatment option for individuals with triple-negative breast cancer.
A 6.7% decrease in breast cancer incidence among US women aged 50+ was reported, likely linked to a decline in hormone therapy use following the Women's Health Initiative study. However, other factors may contribute to this trend, and more research is needed.
A sharp decline in breast-cancer incidence in 2003, followed by relative stabilization, is attributed to the drop in hormone-replacement therapy among postmenopausal women. Researchers estimate a 44,000 fewer breast cancers over two years, with the reduction most evident in estrogen-receptor-positive tumors.
A study published in The Lancet found that women using Hormone Replacement Therapy (HRT) in the UK are 20% more likely to develop and die from ovarian cancer. Researchers analyzed data from over 948,000 postmenopausal women and found a significant increase in ovarian cancer cases and deaths among HRT users.
A sharp decline in breast cancer cases in 2003 may be linked to a decrease in hormone replacement therapy (HRT) use, with prescriptions dropping by 60% between 2001 and 2004. HRT use was associated with an increased risk of breast cancer, particularly among postmenopausal women.
Breast cancer researchers identified the CEACAM6 gene as a unique mediator of aggressiveness and spread in AI-resistant breast cancer cells. The study suggests CEACAM6 may be an important biomarker for metastasis, making it a potential target for novel treatments.
Researchers found a strong association between HRT use and decreased breast cancer incidence, with a 6.7% decline between 2002 and 2003. The lowest rate seen since about 1987 was maintained in 2004, primarily in estrogen-receptor-positive cancers.
The American Association for Cancer Research (AACR) and Susan G. Komen for the Cure have launched a partnership to address cancer disparities and promote prevention. The $2M pledge will support educational outreach, public forums, and research initiatives.
A University of Tennessee researcher has been awarded a $296,000 Komen grant to conduct a groundbreaking study on treating depression in breast cancer patients using behavior therapy. The study aims to determine the effectiveness of two treatments: problem-solving therapy and brief behavior activation therapy.
Two studies suggest that reducing inflammation with aspirin or inhaler medications may help control cancer. One study found regular aspirin users had a 16% reduced risk of developing cancer, while another discovered a link between asthma and increased lung metastasis risk.
Women who delayed first-time pregnancy after age 25 can reduce their breast cancer risk through breastfeeding, a new study suggests. The research found that breastfeeding has a protective effect against both estrogen and progesterone receptor-positive and negative tumors.
Research suggests that genetics, socioeconomic status, and neighborhood environment play a role in cancer incidence and mortality disparities among African-Americans, Hispanics, and Caucasians. A survey found that late-stage cancer diagnosis is more common among older, low-income individuals living in unsafe neighborhoods.
A study found that breast cancer risk is associated with epigenetic changes related to racial group, smoking status, and infant and childhood size. Researchers analyzed DNA methylation patterns in a cohort of women born between 1959 and 1966, finding correlations between these factors and increased breast cancer susceptibility.
Ambassador Nancy Brinker, founder of Susan G. Komen for the Cure, will receive a Centennial Medal for her sustained effort in fighting breast cancer. Lance Armstrong, cancer survivor and seven-time Tour De France winner, will be honored for his advocacy work.
A genetic 'gang of 4' drives the spread of breast cancer to the lungs by promoting tumor growth and metastasis. Researchers discovered that silencing these genes can effectively reduce cancer growth and metastasis in mice.
Researchers at Jefferson University identified a protein called Akt1 that plays a crucial role in helping breast cancer cells spread. The finding could lead to the development of new drugs targeting this protein, potentially slowing or stopping the growth and progression of breast cancer.
A new study found that Hispanic women are diagnosed with more advanced and aggressive breast cancers at a significantly younger age than non-Hispanic women, even when controlling for healthcare access. The research suggests that biological or genetic factors may be driving these racial differences in disease presentation.
A new study led by the University of Georgia finds that older breast cancer survivors experience persistent physical and emotional challenges, with reduced quality of life. The research highlights the need for targeted interventions to improve well-being among this population.
Researchers found that TGF-beta inhibitors can block lung metastases in breast cancer mice treated with radiation or doxorubicin. Monitoring TGF-beta levels could identify at-risk patients for metastatic cancer progression.
Researchers at Vanderbilt University Medical Center have linked treatment-induced TGF-beta levels to increased circulating cancer cells and tumor metastases in a mouse model of breast cancer. Blocking TGF-beta may be clinically useful in combination with primary therapies.
The American Association for Cancer Research (AACR) is honoring world-class cancer researchers who have made significant contributions to the fight against cancer. The winners of the 2007 AACR research achievement awards include Dr. Janet S. Butel, Dr. Harold P. Freeman, and Dr. Alexander Varshavsky.
Early-stage breast cancer patients who receive a single method of treatment, such as tamoxifen or chemotherapy, have improved survival rates. Chemotherapy shows modest yet sustained benefits in relapse-free and overall survival, particularly in younger women and those without ovarian suppression.
The American College of Physicians recommends that clinicians assess each woman's breast cancer risk profile before making a decision about screening mammography. Women between 40-49 years old should weigh the potential benefits and harms of screening, discussing their concerns with their doctor to make an informed choice.
The American College of Physicians released a guideline for mammography screening in women between ages 40 and 49, emphasizing the need for individualized decision-making based on risk factors. The guidelines also highlight the uncertainty surrounding long-term effects of false-positive screening results on women's behavior.
A new study reveals that recent declines in breast cancer mortality rates have been most significant among women with estrogen receptor (ER)-positive tumors and women younger than 70. These groups experienced a 38% decline in mortality from breast cancer, compared to a 19% decline for ER-negative tumors.
The American College of Physicians recommends that mammography screening decisions be made on a case-by-case basis, considering each woman's individual cancer risk and preference. The new guidelines acknowledge the benefits and harms of screening, recommending periodic assessment of breast cancer risk to inform decision-making.
Researchers at the University of Manchester found that older women with breast cancer receive lower levels of care compared to younger women. This includes reduced likelihoods of needle biopsy, surgery, and radiotherapy, which can lead to higher local recurrence rates and mortality.
A major clinical trial shows that MRI scans can quickly identify cancer in the opposite breast of women diagnosed with cancer in one breast. The study found a 90% accuracy rate for detecting contralateral breast cancers.
A multi-center study found that MRI screening detected cancer in the opposite breast in 30% of women with recent breast cancer diagnosis. The cancers were missed by previous mammography and clinical exam. The authors recommend MRI screening for high-risk populations, but emphasize its expense and limited ability to detect calcifications.
An international study by the University of Bonn found that MRI can detect up to 30 cancers in the opposite breast of women with recent unilateral breast cancer diagnoses. The study's results show a 99.6% confidence level that no breast cancer is present if an MRI scan is normal, making preventive mastectomy unnecessary.
Alan Garen and Zhiwei Hu have developed a way to target and destroy tumor blood vessels using nanoparticles. The technology uses a synthetic gene that activates an immune response, allowing for selective destruction of tumors while leaving normal tissue unharmed.
A new study found that triple negative breast cancers are more common among young, poor minority women, particularly African American and Hispanic women. The tumors are also associated with later diagnosis and shorter survival rates, with African American women having the poorest five-year survival rate.
Researchers have developed a new contrast agent that selectively targets and highlights malignant micro-calcifications in the breast, while ignoring similar calcifications found in benign breast conditions. This technique has the potential to improve breast cancer diagnosis by reducing false positives and increasing detection rates.
A study found that only one quarter of general surgeons refer eligible patients for breast reconstruction consultations, resulting in low rates of the procedure in the US. Factors such as surgeon attitudes and patient knowledge play a significant role in referral practices.
A study of 365 surgeons found that only 24% referred three-quarters or more of their patients for reconstruction, citing patient barriers such as inadequate knowledge, cost concerns, and availability of plastic surgeons. The researchers suggest improving decision aids and multidisciplinary care to increase reconstruction rates
A study found that patients who received preventive health exams were more likely to undergo cancer screenings, including colorectal, breast, and prostate cancer testing. The examination may serve as a forum for promoting evidence-based cancer screening.
A new study by the University of Wisconsin-Madison's Center of Excellence in Cancer Communications Research found that accessing high-quality health information online can improve breast cancer patients' opinions about their doctors. The study also discovered a positive correlation between using online services and patient satisfaction...
A large study found that doubling fat intake is linked to a 15% increase in breast cancer risk, regardless of the type of fat consumed. In contrast, higher consumption of lignans, found in plants and whole grains, may be associated with a reduced risk of postmenopausal breast cancer.
Studies found that TP53 mutant tumors in breast cancer are sensitive to a dose-dense epirubicin-cyclophosphamide chemotherapy regimen. This suggests the regimen may be effective for patients with these specific tumor types.
A UBC discovery reveals a protein that changes tumour cells' shape and adhesive quality, allowing them to grow and spread. Researchers aim to develop targeted, non-toxic treatments using 'smart' molecules to block its function.
A new study reveals racial disparities in male breast cancer survival rates, with African-American men facing a higher risk of death. The research analyzed data from over 510 men diagnosed with stage I-III breast cancer and found five-year survival rates of 66% among African-American men versus 90% among white men.
Interferon gamma has been found to play a role in tumor relapse, a development that may lead to the creation of targeted vaccines. This finding is significant as it could help induce specific immune responses in patients, potentially preventing tumor growth and relapse.
Researchers challenge the cancer stem cell hypothesis, suggesting that tumors arise from normal cells and genetic variation rather than a single abnormal stem cell. The study identifies two distinct populations of cancer cells that can be targeted with experimental drugs.
A population-based study found clinically significant variation in breast cancer treatment rates across Manitoba, suggesting the guidelines have not met their objective. The study's findings imply that guideline implementation is not a straightforward process and that other factors influence adoption.
Researchers have used hot nanoprobes to slow tumor growth in laboratory mice without damaging surrounding healthy tissue. The next step is clinical testing in patients with aggressive human breast cancers.
Scientists have developed a method for delivering thermal ablation directly to tumor cells using nanotechnology and molecular imaging. By attaching magnetic iron-containing bioprobes to cancer cells and heating them with an alternating magnetic field, researchers were able to weaken and destroy malignant cells without damaging nearby h...